atopic dermatitis
Conditions
Interventions
Intervention with dupilumab for moderate or higher atopic dermatitis
D008722
Sponsors
MATSUMOTO MAI
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) never administration of dupilumab 2) atopic dermatitis patients who are poor control for existing treatment (EASI score:16 or more and IGA score: 3 or more and Body surface area: 10% or more) 3) age: 15 years or older 4) Patients (or subtitle in case the patient is minor) who got sufficient informed and consent in writing
Exclusion criteria
Exclusion criteria: 1) Contraindications to dupilumab (hypersensitivity, nursing women) 2) Contraindications to obisort(Bronchial asthma, Hyperthyroidism, Severe heart disease, Gastrointestinal ulcer, allergy to obisort, Addison's disease, Gastrointestinal tract or bladder neck obstruction, Epilepsy, parkinsonism, pregnant or may be pregnant women) 3) Patients who are receiving UV therapy, oral cyclosporine, systemic steroid therapy, or need to continue these therapy 4) serious allergy to tape or coating material 5) In addition, patients judged by the investigator to be inappropriate as study subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of sweat volume and latency time in QSART before and after administration of dupilumab | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the following items before and after treatment 1)Skin symptoms (EASI score, rosacea clinical score) 2)Serum TARC value 3)Itching (Visual analog scale) 4)QOL (Patient oriented eczema measure: POEM) 5)Skin flora 6)State-trait anxiety inventory: STAI | — |
Contacts
Public ContactMai Matsumoto
Nagasaki University Hospital
Outcome results
None listed